Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Progressive Multifocal Leukoencephalopathy - Overview
Progressive Multifocal Leukoencephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development
Biological E Ltd
Evrys Bio
Excision BioTherapeutics Inc
Genexine Inc
Humabs BioMed SA
Inhibikase Therapeutics Inc
Neurimmune Holding AG
Pomo Ricerca SRL
Progressive Multifocal Leukoencephalopathy - Drug Profiles
EBT-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efineptakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IkT-01427 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody for John Cunningham Infections and Progressive Multifocal Leukoencephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNJC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Progressive Multifocal Leukoencephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Progressive Multifocal Leukoencephalopathy - Dormant Projects
Progressive Multifocal Leukoencephalopathy - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: NeoImmuneTech receives FDA orphan drug desigtion for NT-I7 (efineptakin alfa) for the treatment of progressive multifocal leukoencephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Biological E Ltd, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Evrys Bio, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Genexine Inc, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Humabs BioMed SA, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Inhibikase Therapeutics Inc, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H2 2020
Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H2 2020
Progressive Multifocal Leukoencephalopathy - Dormant Projects, H2 2020